

Response to Cyclosporine & Eltrombopag in Primary Graft Failure after Autologous transplant in Myeloma

Kumar Nikhil M¹, Nathany Shrinidhi¹, Swaminathan Anusha¹, Yadav Chitresh¹, Panda Rastogi Neha², Dua Vikas¹, Bhargava Rahul¹

¹Hematology and BMT, Fortis Memorial Research Institute, Gurugram, India, ²Infectious Diseases, Fortis Memorial Research Institute, Gurugram, India

Abstract

Primary graft failure is an uncommon but serious complication that occurs when the hematopoietic engraftment fails to occur within the expected timeframe. Here, we report the case of a 63-year-old female with multiple myeloma who developed primary graft failure after Autologous stem cell transplant (ASCT). Despite initial concerns regarding his poor prognosis, the patient was successfully treated with cyclosporine as a novel rescue therapy. This condition necessitates prolonged hospitalization, frequent transfusions, and poses a high risk of life-threatening infections due to persistent cytopenias. The incidence of primary graft failure in myeloma patients undergoing ASCT has been reported to be less than 1% in recent studies. Despite its low occurrence, the clinical consequences of this complication are profound, contributing significantly to morbidity and mortality in this patient population. Cyclosporine has emerged as a promising therapeutic agent for the management of primary graft failure. The mechanism of action is believed to involve immunosuppression. This case underscores the potential utility of cyclosporine as a therapeutic option in patients with primary graft failure following ASCT, offering an alternative to the more invasive and risky strategy of allogeneic stem cell transplant.

Key words Myeloma, Graft failure, cyclosporine

Submitted March 13, 2025; Accepted August 5, 2025; Published online November 7, 2025; Issued online November 25, 2025

Correspondence: Rahul Bhargava, Department of Hematology and BMT Fortis Memorial Research Institute Sector -44, Opposite Huda City Centre, Gurugram, Haryana 122003, India

E-mail: Bhargava777@gmail.com

Introduction

Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the excessive production of monoclonal immunoglobulins, which can result in significant end-organ damage, including renal failure, bone lesions, and hematologic complications such as anemia¹. The treatment landscape for multiple myeloma has evolved significantly, with autologous stem cell transplantation (ASCT) serving as the cornerstone for eligible patients with newly diagnosed disease. High-dose melphalan conditioning followed by stem cell rescue improves progression-free survival in these patients². Despite the advancements in treatment, challenges remain in managing the rare but potentially devastating complications of ASCT.

Primary graft failure is an uncommon but serious complication that occurs when the hematopoietic engraftment fails to occur within the expected timeframe. It is defined by a peripheral blood absolute neutrophil count (ANC) of less than 500/ μ L and a platelet count of less than 20,000/ μ L by day 21 post-transplant³. Primary graft failure can result in prolonged pancytopenia, increased risk of infections, and ultimately, poor prognosis if left unaddressed. There are no universally accepted treatment strategies for this condition, and management remains challenging. Various approaches have been explored, including autologous stem cell boost (Cook et al., 2022), second autologous transplant, and allogeneic transplant (Pottinger et al., 2002). However, these interventions do not guarantee success and often come with their own risks and complications. Empirical

cyclosporine therapy has been shown to promote neutrophil engraftment within a median of 5-7 days^{3,4}, while eltrombopag is widely used for treating poor graft function post allogeneic stem cell transplant⁵.

Here, we report the case of a 63-year-old female with multiple myeloma who developed primary graft failure after ASCT. Despite initial concerns regarding her poor prognosis, the patient was successfully treated with cyclosporine and eltrombopag as a novel rescue therapy. This case illustrates the potential of cyclosporine and eltrombopag combination as an effective strategy for reversing primary graft failure and highlights the need for further investigation into alternative therapies in such cases.

Case Report

A 63-year-old female was diagnosed with IgG kappa multiple myeloma in February 2024. At baseline, the patient had a Revised International Staging System (R-ISS) score of 2, with no high-risk cytogenetic abnormalities detected on fluorescence in situ hybridization (FISH). She received four cycles of induction therapy with the Velcade-Revlimid-Dexa (VRd) regimen (bortezomib 1.3 mg/m² subcutaneously weekly, lenalidomide 20 mg once daily for 21 days of a 28-day cycle, and dexamethasone 40 mg weekly). After completing the induction, she achieved a very good partial response (VGPR) as per the International Myeloma Working Group (IMWG) criteria and proceeded to ASCT.

Pre-transplant evaluation was unremarkable, and the patient did not develop any infectious complications during induction therapy or prior to transplantation. Stem cell mobilisation was achieved with standard G-CSF plus Plerixafor protocol (G-CSF 10 mcg/kg for 5 days and Plerixafor 0.24 mg/kg 11 hours prior to apheresis) and CD34 dose of 11 million/kg was collected. Stem cell product was stored at 4 degree celsius in the blood bank for a period of 24 hours. Conditioning with melphalan (200 mg/m²) was administered after stem cell collection on the same day, followed by stem cell infusion 24 hours later at a CD34 dose of 11 million/kg. Growth factor support was initiated on day +2. Patient was also initiated on valacyclovir and fluconazole prophylaxis as per standard protocols from day +2. Antiemetics like Ondansetron and Metoclopramide were administered, when required.

The patient developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 oral and abdominal mucositis starting on day +6, which was managed conservatively and resolved by day +13. Due to persistent cytopenia, a bone marrow biopsy was performed on day +24, revealing hypocellular marrow with less than 5% cellularity. Infective work up was done to rule

out transient marrow aplasia. Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Adenovirus, Parvovirus PCR was negative. Blood and Urine cultures were sterile and a CT scan of the chest did not reveal any active infection. In response, treatment with eltrombopag (150 mg once daily) and cyclosporine (3 mg/kg/day in two divided doses) was initiated on day +26.

On day +30, the patient developed probable fungal pneumonia, which was managed with appropriate antifungal therapy. Neutrophil engraftment was achieved by day +35, and platelet engraftment was noted by day +40. The patient was discharged from the hospital, and blood counts fully recovered over the following month. The trends of hemogram are depicted in **Figure 1(A-C)** and **Table 1**.

The patient received one cycle of VRd consolidation starting on day +75 but developed recurrent cytopenias during lenalidomide therapy. A bone marrow biopsy on day +100 demonstrated minimal residual disease (MRD) negativity by flow cytometry (sensitivity of 10⁻⁴), and a PET-CT scan showed a complete metabolic response. Bortezomib maintenance therapy (2 mg subcutaneously every 15 days) was initiated on day +110.

As of the most recent follow-up, 8 months post-transplant, the patient remains in complete remission (CR).

Discussion

Primary graft failure is an exceedingly rare but often fatal complication in multiple myeloma patients undergoing ASCT. This condition necessitates prolonged hospitalization, frequent transfusions, and poses a high risk of life-threatening infections due to persistent cytopenias. The incidence of primary graft failure in myeloma patients undergoing ASCT has been reported to be less than 1% in recent studies^{3,6}. Despite its low occurrence, the clinical consequences of this complication are profound, contributing significantly to morbidity and mortality in this patient population.

The pathogenic mechanisms and risk factors for graft failure in ASCT remain poorly understood. Several factors have been implicated in the delayed engraftment of hematopoietic stem cells, including stem cell dose and viability, the duration between diagnosis and transplant, the conditioning regimen, the effect of prior treatments on the bone marrow microenvironment, and peri-transplant infectious complications⁷. Lower CD34+ cell count (less than 3 million/kg), transfusion dependence before transplant, and low pre-transplant platelet count (less than 150,000/mm³) have been found to be statistically significant predictors of delayed neutrophil and platelet engraftment⁸. Additionally, the suppression of hematopoiesis by auto-reactive T lymphocytes is




Figure 1. Trends of hemogram
A: Depicts changes in the Hemoglobin (g/dL) concentration. **B:** Depicts changes in the total leukocyte count (blue trendline) (cells/cu mm) and the Absolute neutrophil count (orange trendline) (cells/cu mm). **C:** Depicts changes in the Platelet count (cells/cu mm).
The black down arrow in all three figures depicts day +26, which is the day of initiation of cyclosporine and eltrombopag.

Table 1. Table showing trends of hemogram

Date	22-04-24	24-04-24	26-04-24	27-04-24	28-04-24	29-04-24	30-04-24	01-05-24	02-05-24	03-05-24	10-05-2024	31-05-2025	06-01-2025
HEMOGLOBIN	11.3	10.4	10	9.3	9.8	9.5	9.7	9.3	9.1	8.7	7.0	7.8	10.0
Total Leucocyte Count (TLC)	45.42	27.83	1.91	4.5	0.51	0.1	0.04	0.04	0.02	0.01	0.04	0.63	5.15
ABSOLUTE NEUTROPHIL COUNT	33.16	22.26	1.77	4.23	0.34	0	0	0	0	0	0	0.52	1.98
PLATELET	350	179	138	110	87	65	42	24	9	50	65	20	48

thought to contribute to primary graft failure, although the exact mechanism remains unclear³.

Empirical cyclosporine therapy has shown encouraging results in the treatment of primary graft failure post ASCT⁴. The mechanism of action is believed to involve suppression of autoreactive T lymphocytes, which reduces immune-mediated rejection of the graft and promotes hematopoietic recovery⁹. Eltrombopag, a thrombopoietin receptor agonist, has been reported to improve platelet counts and overall hematopoietic recovery in patients with poor graft function (PGF) post stem cell transplant⁵. In our case, the patient underwent ASCT following four cycles of chemotherapy with the VRd regimen. Pre-transplant blood counts were normal, and CD34 dose of 11 million/kg was considered adequate. Notably, no infectious complications arose in the

first three weeks following the transplant. However, despite these favorable conditions, the patient experienced primary graft failure, and no apparent cause was identified.

Given the absence of cryopreserved stem cells for a potential stem cell boost, a trial of cyclosporine and eltrombopag was initiated prior to considering an allogeneic transplant. Neutrophil engraftment occurred on day +35, and platelet engraftment was achieved by day +40, after starting cyclosporine and eltrombopag. Remarkably, cyclosporine and eltrombopag could be tapered off after one month, suggesting that this approach facilitated hematopoietic recovery. However, since the neutrophil engraftment occurred by D+35, possibility of spontaneous recovery cannot be excluded in our patient. Similar positive outcomes were observed in a small

study by Cubillas et al., where four out of five patients with primary graft failure after autologous transplant successfully engrafted following treatment with cyclosporine with median time of 5 days to achieve absolute neutrophil count (ANC) > 500/uL³.

This case underscores the potential utility of cyclosporine and eltrombopag as a therapeutic option in patients with primary graft failure following ASCT, offering an alternative to the more invasive and risky strategy of allogeneic stem cell transplant. Allogeneic transplant in this patient cohort has been associated with poor outcomes, including a high risk of graft-versus-host disease and relapse¹⁰. Therefore, cyclosporine with eltrombopag therapy should be considered as a first-line treatment in such cases, especially in the absence of other effective options.

Author Contributions

NMK: primary physician, RB and VD: team leads and supervision for treatment, administration and revision of manuscript, CY and AS: adult hematologists involved in patient care and data curation, SN: wrote the report, NRP infectious disease physician to manage infectious complications. MNK and SN have contributed equally.

Conflicts of Interest

The author declares no conflict of interest. Disclosure form provided by the author are available on the website.

References

1. Cowan A, Green D, Kwok M, Lee SS, Coffey D, Holmberg L, et al. Diagnosis and Management of Multiple Myeloma: A Review. *JAMA*. 2022; **327**: 464-77.
2. Al Hamed R, Bazarbachi AH, Malard F, Harousseau J-L, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. *Blood Cancer J*. 2019; **9**: 44.
3. Hama Sphere, Cubillas D, Quesada Sanchez M, Martinez Sanchez P, Robles MC, Pina MS, et al. P1328 Successful treatment of graft failure in autologous stem cell transplantation with cyclosporine. 2022. <https://onlinelibrary.wiley.com/doi/10.1097/01.HS9.0000848176.34514.00> [Accessed: 13 March 2025]
4. Kamble RT, Sethi S, Selby GB. Re: failure to engraft after autologous stem cell transplantation: possible therapeutic role of cyclosporine. *Biol Blood Marrow Transplant*. 2005; **11**: 74.
5. Halahleh K, Al-Ya'Goub M, Ma'koseh M, Al-Far R, Da'na W, Pharm RA, et al. Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation. *Blood Cell Ther*. 2025; **8**: 160-6.
6. Cook J, Gonsalves WL, Gertz MA, Visram A, Warsame R, Lacy MQ, et al. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. *Bone Marrow Transplant*. 2022; **57**: 1007-9.
7. Ergene U, Cağirgan S, Pehlivan M, Yilmaz M, Tombuloğlu M. Factors influencing engraftment in autologous peripheral hematopoietic stem cell transplantation (PBSCT). *Transfus Apher Sci*. 2007; **36**: 23-9.
8. Lutfi F, Skelton Iv WP, Wang Y, Rosenau E, Farhadfar N, Murthy H, et al. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. *Hematol Oncol Stem Cell Ther*. 2020; **13**: 23-31.
9. Cardenas ME, Zhu D, Heitman J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. *Curr Opin Nephrol Hypertens*. 1995; **4**: 472-7.
10. Yin X, Tang L, Fan F, Jiang Q, Sun C, Hu Y. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. *Cancer Cell Int*. 2018; **18**: 62.

<https://doi.org/10.31547/bct-2025-006>

Copyright ©2025 Asia-Pacific Blood and Marrow Transplantation Group (APBMT). This is an open access article distributed under CC BY-NC license (<https://creativecommons.org/licenses/by-nc/4.0/>).